No connection

Search Results

SCLX

BEARISH
$6.9 Live
Scilex Holding Company · NASDAQ
$3.6 52W Range $34.27
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 19, 2026
Market cap
$48.53M
P/E
N/A
ROE
N/A
Profit margin
N/A
Debt/Equity
N/A
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
SCLX exhibits severe financial distress, anchored by a weak Piotroski F-Score of 2/9 and a critical liquidity crisis evidenced by a Current Ratio of 0.08. The company is experiencing a collapse in top-line growth with YoY revenue declining by 67.80%, coupled with an unsustainable operating margin of -782.02%. Negative book value (P/B -0.23) and a history of massive earnings misses suggest a high risk of insolvency. The overall profile is one of a failing micro-cap with no fundamental support for its current valuation.

Key Strengths

Gross margin remains positive at 64.96%
Forward P/E of 9.45 suggests speculative expectations of future profitability
Recent 1-year price change is slightly positive (+14.6%) despite fundamental decay
Positive Q/Q EPS growth (though still deeply negative)
Operating in the high-demand Healthcare/Drug Manufacturing sector

Key Risks

Extreme liquidity risk with a Current Ratio of 0.08 and Quick Ratio of 0.05
Severe revenue contraction (-67.80% YoY)
Negative shareholder equity (Price/Book of -0.23)
Consistent and massive earnings misses (Average surprise -1986.02%)
High probability of bankruptcy or extreme dilution given the cash burn and debt profile

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
7
Weak
Value
5
Future
10
Past
15
Health
5
Dividend
0
AI Verdict
Critical Failure
Key drivers: Insolvency risk, Revenue collapse, Negative equity, Extreme earnings misses
Confidence
95%
Value
5/100

P/B of -0.23 indicates the company's liabilities exceed its assets.

Positives
No standout positives identified.
Watchpoints
  • Negative Price/Book ratio
  • No Graham Number available due to lack of earnings/assets
Future
10/100

Growth metrics are in a state of freefall.

Positives
  • Speculative forward P/E
Watchpoints
  • Revenue growth is -67.80%
  • Operating margins are deeply negative
Past
15/100

Long-term trend is a near-total loss of shareholder value.

Positives
No standout positives identified.
Watchpoints
  • 5-year price change of -98%
  • Consistent failure to meet earnings estimates
Health
5/100

The company cannot meet its short-term obligations with current assets.

Positives
No standout positives identified.
Watchpoints
  • Piotroski F-Score of 2/9
  • Current Ratio of 0.08
Dividend
0/100

Dividend strength is 0/100.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • No capacity to pay dividends

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$6.9

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for SCLX and closest competitors.

Updated 2026-04-17
SCL
Scilex Holding Company
Primary
5Y
-98.0%
3Y
-98.6%
1Y
+14.6%
6M
-46.0%
1M
-10.6%
1W
+1.5%
ELU
Elutia Inc.
Peer
5Y
-91.4%
3Y
-20.8%
1Y
-53.7%
6M
+28.2%
1M
-2.6%
1W
+4.6%
SCY
SCYNEXIS, Inc.
Peer
5Y
-85.1%
3Y
-65.7%
1Y
+22.8%
6M
+47.0%
1M
+23.3%
1W
+11.0%
NTR
Nutriband Inc.
Peer
5Y
-28.9%
3Y
+17.2%
1Y
-16.9%
6M
-45.8%
1M
+7.4%
1W
+4.1%
HYF
MindWalk Holdings Corp.
Peer
5Y
-91.3%
3Y
-62.5%
1Y
+166.8%
6M
-40.9%
1M
-16.4%
1W
-6.1%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
9.45
PEG Ratio
N/A
P/B Ratio
-0.23
P/S Ratio
1.6
EV/Revenue
5.49
EV/EBITDA
-0.62
Market Cap
$48.53M

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -782.01%
Gross Margin 64.96%
ROE N/A
ROA -74.33%

Growth

Revenue and earnings growth rates

Revenue Growth -67.8%
Earnings Growth N/A
Q/Q Revenue Growth -67.83%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
N/A
Current Ratio
0.08
Weak
Quick Ratio
0.05
Poor
Cash/Share
$1.56

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
45.5%
Op. Margin
-782.0%
Net Margin
-690.8%
Total Assets
$0.4B
Liabilities
$0.6B
Equity
$-0.2B
Debt/Equity
-2.78x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-04-10
$-1.17
-149.3% surprise
2026-03-12
$N/A
2025-11-14
$-21.29
-5093.4% surprise
2025-08-13
$-7.42
-715.4% surprise

Healthcare Sector Comparison

Comparing SCLX against 447 companies in the Healthcare sector (26 bullish, 140 neutral, 281 bearish)
Revenue Growth
-67.8%
This Stock
vs
147.85%
Sector Avg
-145.9% (Slower)
Current Ratio
0.08
This Stock
vs
4.68
Sector Avg
-98.3% (Weaker)

Similar Companies

Peer comparison within the same industry

SCLX Scilex Holding Company
BEARISH
Mkt Cap
$49M
P/E
-
ROE
-%
Price
$6.9
ELUT Elutia Inc.
BULLISH
Mkt Cap
$49M
P/E
-
ROE
-%
Price
$1.14
 Compare with SCLX
SCYX SCYNEXIS, Inc.
BULLISH
Mkt Cap
$50M
P/E
-
ROE
-16.5%
Price
$1.11
 Compare with SCLX
NTRB Nutriband Inc.
BEARISH
Mkt Cap
$50M
P/E
-
ROE
-136.1%
Price
$4.08
 Compare with SCLX
HYFT MindWalk Holdings Corp.
BEARISH
Mkt Cap
$50M
P/E
-
ROE
-58.8%
Price
$1.07
 Compare with SCLX

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

SCILEX HOLDING CO
Beneficial Owner of more than 10% of a Class of Security
Sell
2025-12-30
20,657,300 shares · $270,814,177
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

10-K
10-K
2026-04-10

SCLX filed its annual 10-K report on April 10, 2026. The provided excerpts do not contain specific financial metrics or detailed risk disclosures, limiting the available analysis of the company's financial performance and risk profile.

8-K
8-K
2026-03-13
8-K
8-K
2026-03-13

Scilex Holding Company Limited reported a material event on March 13, 2026, likely related to its annual financial reporting cycle.

8-K
8-K
2026-02-20
8-K
8-K
2026-02-03

Scilex Holding Company Limited filed an 8-K on February 3, 2026, likely to report its fourth-quarter and full-year financial results.

8-K
8-K
2026-02-02

Scilex Holding Company Limited filed an 8-K on February 2, 2026, likely to announce its fourth quarter and full-year financial results.

8-K
8-K
2025-12-30
8-K
8-K
2025-12-22
8-K
8-K
2025-12-17
S-1
S-1
2025-12-16

SCLX filed an S-1 registration statement on December 16, 2025, indicating its intention to register securities for a public offering.

8-K
8-K
2025-12-12
8-K
8-K
2025-12-11
8-K
8-K
2025-12-05
8-K
8-K
2025-12-01
8-K
8-K
2025-11-24
Data sourced from SEC EDGAR. AI summaries generated automatically.

Past News Coverage

Recent headlines mentioning SCLX from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile